Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522656 | 0.86 | CYP1A2 (0.52) | ACHEMAOB | |
| SCHEMBL20707236 | 0.86 | CYP1A2 (0.52) | ACHEMAOB | |
| SCHEMBL752923 | 0.85 | CYP1A2 (0.56) | ACHE | |
| SCHEMBL2399729 | 0.77 | MAOB (0.77) | ACHEMAOB | |
| SCHEMBL2400817 | 0.76 | MAOB (0.75) | ACHEMAOB | |
| SCHEMBL13590254 | 0.76 | ACHE (0.73) | ACHEMAOB | |
| SCHEMBL7434719 | 0.75 | ALDH1A1 (0.52) | ACHE | |
| SCHEMBL13590077 | 0.73 | ACHE (0.68) | ACHEMAOB | |
| SCHEMBL14729859 | 0.73 | MAOB (0.77) | ACHEMAOB | |
| SCHEMBL25443471 | 0.72 | MAOB (0.74) | ACHEMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | ACHE 4533/4885MAOB 3130/4885 |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | ACHE 4821/4885MAOB 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.